Compare Hyatt Hotels Corporation (H) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs IDEXX Laboratories, Inc. — how do they compare? Hyatt Hotels Corporation trades at $177.15 (market cap $16.27B), while IDEXX Laboratories, Inc. trades at $571.7 (market cap $46.22B). The key difference: IDEXX Laboratories, Inc. is far larger — about 2.8× Hyatt Hotels Corporation's market cap, and Hyatt Hotels Corporation pays a 0.35% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| H | IDXX | |
|---|---|---|
Market Cap | $16.27B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $766.68 |
52-Week Low | $135.42 | $526.44 |
Enterprise Value | $20.17B | $47.12B |
Dividend Yield | 0.35% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels Corp (H) trades at $176.29, up 3.65% today, with a bearish technical outlook but strong recent earnings beats. The stock shows a high P/E of 213.14 and modest net margin of 1.1%, while cash flow trends are volatile. Analyst consensus is mixed with a $199.55 price target, and recent news highlights valuation concerns amid growth initiatives.
Outlook balances operational momentum from fee growth and RevPAR gains against rich valuation and debt risks. Investment opportunity lies in sustained travel demand, but risks include project delays, regional weakness, and high leverage. The stock requires patience for growth to justify premium multiples.
IDEXX Laboratories (IDXX) trades at $571.44, down 4.08% over the past day, amid a mixed technical and strong fundamental backdrop. The stock shows a bullish trend in moving averages but overbought RSI readings near 73. Recent Q2 2026 earnings beat expectations with 9% organic revenue growth, and the company raised full-year EPS guidance. Profitability remains robust with a 25.03% net income margin and 74.21% ROE.
The outlook is positive given strong earnings momentum, high analyst buy ratings, and a consensus price target of $683.33 implying ~20% upside. Risks include premium valuation multiples and potential market volatility. The stock presents a growth opportunity supported by durable competitive advantages in veterinary diagnostics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
